High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer

Bone Marrow Transplantation

Volumn 34, Issue 7, 2004, Pages 637-643

  Bojko, P ^a   Welt, Anja ^a   Schleucher, R ^a   Borquez, D ^a   Scheulen, M E ^a   Vanhoefer, U ^a   Poettgen, C ^a   Stuschke, M ^a   Broelsch, C E ^a   Stamatis, G ^b   Wilke, H ^a   Seeber, S ^a   Harstrick, A ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b RUHRLANDKLINIK   (Germany)

Author keywords

Breast; Cancer; Combined modality; HDC; Oligometastatic

Indexed keywords

ANASTROZOLE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GOSERELIN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MITOXANTRONE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; THIOTEPA;

ABSCESS; ADULT; ALLERGIC REACTION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; BREAST SURGERY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC CYSTITIS; HUMAN; LEUKOPENIA; LIVER METASTASIS; LIVER SURGERY; LUNG INFECTION; METASTASIS POTENTIAL; MORTALITY; MULTIMODALITY CANCER THERAPY; PLEURA EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAFETY; STOMATITIS; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUCOVORIN; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 5044249324     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704613     Document Type: Article

References (27)

1. Feldman AL, Welch JP. Long-term outcome in women less than 30 years of age with breast cancer. J Surg Oncol 1998; 68: 193-98.
2. Greenberg PA, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-2205.
3. Peters WP, Dansey RD, Klein JL et al. High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. Oncologist 2000; 5: 1-13.
4. Antman KH. Randomized trials of high-dose chemotherapy for breast cancer. Biochim Biophys Acta 2001; 1471: 89-98.
5. Schulman KA, Stadtmauer EA, Reed SD et al. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Bone Marrow Transplant 2003; 31: 205-210.
6. Nieto Y. The verdict is not yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica 2003; 88: 201-211.
7. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-1376.
8. Dunphy FR, Spitzer G, Buzdar AU et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207-1216.
9. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
10. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomized trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356: 1384-1391.
11. Stadtmauer EA, O'Neill AO, Lori MS et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1069-1076.
12. Berry DA, Broadwater G, Klein JP et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the autologous blood and marrow transplant registry. J Clin Oncol 2002; 20: 743-750.
13. Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin Oncol 2002; 20: 620-623.
14. Bojko P, Stellberg W, Kuedde C et al. Kinetic study of CD34+ cells during peripheral blood stem cell collections. J Clin Apheresis 1999; 14: 18-25.
15. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-3365.
16. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974-984.
17. Kamby S, Sengelov L. Pattern of dissemination and survival following isolated loco-regional recurrence of breast cancer. A prospective study with more than 10 years of follow up. Breast Cancer Res Treat 1997; 45: 181-192.
18. Bathe OF, Kaklamanos IG, Moffat FL et al. Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer. Surg Oncol 1999; 8: 35-42.
19. Pocard M, Pouillart P, Asselain B et al. Hepatic resection in metastatic breast cancer: results and prognostic factors. Eur J Surg Oncol 2000; 26: 155-159.
20. Elias D, Maisonnette F, Druet-Cabanac M et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg 2003; 185: 158-164.
21. Wilke H, Klaassen U, Achterrath W et al. Phase I/II study with a weekly 24-h infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. Ann Oncol 1996; 7: 55-58.
22. Nieto Y, Martin M, Alonso JL et al. Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin. Breast Cancer Res Treat 1998; 50: 167-174.
23. Nieto Y, Nawaz S, Jones RB et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002; 20: 707-718.
24. Bojko P, Akca A, Seeber S. Outcome of 67 patients with solid tumors relapsed after high-dose chemotherapy and peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 31: 995-1000.
25. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouacil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669.
26. Rivera E, Holmes FA, Buzdar AU et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J 2002; 8: 2-9.
27. Smith TJ, Davidson NE, Schapira DV et al. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999; 17: 1080-1082.